This article has been updated from a previous version.

NEW YORK, July 2 - The future of an R&D collaboration between Celera Genomics and stem-cell company Geron has been cast into doubt after Geron laid off roughly one-third of its staff and since both companies have refocused their research initiatives, GenomeWeb has learned.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.